Olema Oncology Announces Preclinical Data Show Potent Oral KAT6A Degraders Inhibit ER+/HER2- Breast Cancer Growth
Olema Oncology reported promising preclinical data on its selective KAT6A degraders, showing strong antitumor activity and good tolerability in ER+/HER2- breast cancer models. These oral compounds demonstrated potent antiproliferative effects in both ESR1-mutant and wild-type models, leading to significant tumor growth inhibition and regression. The findings suggest KAT6A degradation could be a valuable new therapeutic strategy for breast cancer, complementing Olema's existing KAT6 inhibitor.
Experimental drugs shrank breast tumors in one model and slowed growth in two others.
Olema Oncology announced promising preclinical results for its selective KAT6A protein degraders in ER+/HER2- breast cancer models. Four compounds (OP-1 through OP-4) demonstrated near-complete KAT6A degradation, inhibited cancer cell proliferation, and caused tumor regression in one model while slowing growth in two others. These findings suggest the potential for once-daily oral dosing in humans and will be presented at the EORTC-NCI-AACR Symposium.
Olema Oncology to Participate in Upcoming Investor Conferences
Olema Oncology, a biopharmaceutical company focused on breast cancer therapies, announced its participation in three upcoming investor conferences: the Evercore Healthcare Conference on November 30, 2026, the Citi Global Healthcare Conference on December 1, 2026, and the Piper Sandler Healthcare Conference on December 2, 2026. The company will present in fireside chats, which will be webcast live on its investor relations website. Olema is advancing its lead candidate, palazestrant, in Phase 3 trials and OP-3136 in a Phase 1 study.
Olema Oncology to Participate in Upcoming Investor Conferences
Olema Oncology, a clinical-stage biopharmaceutical company focused on breast cancer therapies, announced its participation in three upcoming investor conferences in late November and early December 2026. The company will present at the 9th Annual Evercore Healthcare Conference, Citi's 2026 Global Healthcare Conference, and the Piper Sandler 38th Annual Healthcare Conference. Live webcasts and recordings of these presentations will be available on Olema's investor relations website.
Olema Oncology (Nasdaq:OLMA) - Stock Analysis
Olema Oncology is a clinical-stage biopharmaceutical company focused on developing therapies for women's cancers, with a current market cap of US$662.3m. The company's lead product candidate, palazestrant, is in Phase 3 clinical trials for ER+/HER2- metastatic breast cancer, while OP-3136, a KAT6 inhibitor, is in Phase 1 studies. Despite being currently unprofitable, analysts forecast revenue growth and the company holds a significant cash runway into late 2028.
Olema Oncology (OLMA) moves executive offices to South San Francisco.
Olema Pharmaceuticals, Inc. has officially changed its corporate name to Olema Oncology, Inc., effective November 12, 2026, reflecting its focus on cancer therapies. The company's common stock will continue to trade on The Nasdaq Global Select Market under the ticker symbol "OLMA." Concurrently, Olema Oncology has relocated its principal executive offices from San Francisco to South San Francisco.
Insiders At Olema Pharmaceuticals Sold US$9.2m Of Stock Potentially Indicating Weakness
Insiders at Olema Pharmaceuticals (NASDAQ:OLMA) sold US$9.2 million worth of stock over the past year, primarily at an average price of US$27.36, which was higher than the current trading price. While there were no insider stock purchases in the last year, insiders still own 2.7% of the company, valued at approximately US$19 million, suggesting some alignment with shareholders despite the selling activity. The article advises caution due to these insider sales and notes some warning signs for the company.
Olema Oncology Announces Corporate Name Change
Olema Pharmaceuticals, Inc. has officially changed its corporate name to Olema Oncology, Inc., effective November 12, 2026. The company's common stock will continue to trade on the Nasdaq Global Select Market under the ticker symbol "OLMA." This change reflects the company's focus as a clinical-stage biopharmaceutical company dedicated to developing targeted therapies for breast cancer and other endocrine-driven cancers.
Olema Pharmaceuticals Q3 Results: Loss widens 49% YoY to $(0.73)
Olema Pharmaceuticals Inc. reported a Q3 loss of $(0.73) per share, significantly missing analyst estimates of $(0.63) by 17.74%. This represents a 48.98% widening of losses compared to $(0.49) per share in the same period last year. The results indicate a higher-than-expected operational shortfall for the quarter.
Olema Reports Q3 2026 Results, $413.8 Million in Cash and OPERA-01 Data on Track for 2027
Olema Pharmaceuticals reported a net loss of $73.6 million in Q3 2026, an increase from the previous year, as the company continued investments in late-stage trials. Despite the loss, Olema ended the quarter with $413.8 million in cash, cash equivalents, and marketable securities and remains on track to release top-line results from its pivotal OPERA-01 trial in Q1 2027. The company is also advancing other clinical programs and will present data at upcoming symposiums.
Olema Oncology Reports Third Quarter 2026 Financial and Operating Results
Olema Oncology announced its third-quarter 2026 financial and operating results, highlighting that it is on track to release top-line data from its pivotal Phase 3 OPERA-01 trial in Q1 2027. The company reported continued strong enrollment in its OPERA-02 trial and the Phase 1b/2 study of OP-3136, and ended the quarter with $413.8 million in cash. Additionally, Jason O’Byrne was appointed as the new Chief Financial Officer.
Olema Pharmaceuticals, Inc. (OLMA) Misses Q3 EPS by 9c
Olema Pharmaceuticals, Inc. (OLMA) reported its Q3 EPS, missing analyst estimates by $0.09. The company posted an EPS of ($0.73), while analysts had predicted ($0.64). This financial update provides key information for investors following OLMA's performance.
Form 8K Olema Pharmaceuticals Inc For: 10 November By Investing.com
Olema Pharmaceuticals Inc. filed a Form 8K for November 10th. The article provides this basic announcement along with current stock market data and other news headlines. The stock symbol OLMA is mentioned, showing a -1.22% change.
Candriam S.C.A. Purchases 433,334 Shares of Olema Pharmaceuticals, Inc. $OLMA
Candriam S.C.A. significantly increased its stake in Olema Pharmaceuticals (NASDAQ:OLMA) during the third quarter, purchasing an additional 433,334 shares to bring its total holdings to 1.18 million shares valued at $10.3 million. This comes as Olema Pharmaceuticals reported a quarterly loss that missed analyst expectations, with shares trading below key moving averages. Despite varying analyst price targets, the company currently holds an average "Moderate Buy" rating.
OLMA: SEC Form 10-Q filed by Olema Pharmaceuticals Inc.
Olema Pharmaceuticals Inc. (OLMA) filed its Q3 2026 10-Q report, revealing 87,606,263 shares outstanding and 13,594,149 pre-funded warrant shares. The report also detailed past equity financings, including a $204.8 million net follow-on offering in November 2025 and a $250 million private placement in 2024. The filing highlights potential future dilution from pre-funded warrants.
Weekly Recap: Three-study data at symposium and 261,300 new-hire options
Olema Pharmaceuticals, Inc. (OLMA) is set to present data from three studies at the San Antonio Breast Cancer Symposium from December 8-11, covering OP-3136 with fulvestrant, and palazestrant with everolimus or atirmociclib. Additionally, the company granted options for 261,300 shares to 10 new hires, effective November 2, 2026, with an exercise price of $7.07, a 10-year term, and four-year vesting.
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Stock Now Rated "Moderate Buy" by Sell-Side Brokerages
Olema Pharmaceuticals (NASDAQ:OLMA) has received a "Moderate Buy" consensus rating from analysts, with 11 out of 13 recommending a buy and an average 12-month price target of $40.60. Despite the positive analyst sentiment, the company's shares are near their 12-month low, and it reported a quarterly EPS miss of negative $0.61 against an estimated negative $0.55. Institutional investors hold a significant portion of the stock, with 91.78% owned by hedge funds and other large investors.
Olema Oncology to Present Combination Data from the Palazestrant and OP-3136 Programs at the 2026 San Antonio Breast Cancer Symposium
Olema Oncology announced it will present clinical data from three Phase 1b/2 and Phase 1 studies at the 2026 San Antonio Breast Cancer Symposium (SABCS) in December. The presentations will cover combination data for OP-3136 with fulvestrant, palazestrant with everolimus, and palazestrant with atirmociclib, all in patients with ER+, HER2- advanced or metastatic breast cancer. This highlights Olema's ongoing efforts to develop novel targeted therapies for breast cancer.
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Pharmaceuticals, Inc. announced it has granted stock options to ten new employees to purchase an aggregate of 261,300 shares of the Company's common stock. These awards were made effective November 2, 2026, under the Company's 2022 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options vest over four years and have an exercise price of $7.07 per share.
Olema Oncology to Participate in Upcoming Investor Conferences
Olema Pharmaceuticals, Inc. (Nasdaq: OLMA) announced its participation in four upcoming investor conferences in November 2026, including the Guggenheim 3rd Annual Healthcare Innovation Conference, Stifel 2026 Healthcare Conference, UBS Global Biopharma Conference, and Jefferies Global Healthcare Conference. The company will conduct fireside chats at each event, with webcasts available on its investor relations website. Olema Oncology is a clinical-stage biopharmaceutical company focused on targeted therapies for breast cancer.
Olema Oncology to Participate in Upcoming Investor Conferences
Olema Oncology (OLMA) announced its participation in four investor conferences with fireside chats scheduled from November 10 to November 18, 2026. These events include the Guggenheim Healthcare Innovation Conference in Boston, the Stifel 2026 Healthcare Conference in New York, and the UBS Global Biopharma Conference and Jefferies Global Healthcare Conference, both in London. Live webcasts and recordings of these presentations will be available on Olema’s investor relations website.
Olema Oncology to Participate in Upcoming Investor Conferences
Olema Pharmaceuticals, Inc. (Nasdaq: OLMA) announced its participation in four upcoming investor conferences in November 2026. These include the Guggenheim 3rd Annual Healthcare Innovation Conference, Stifel 2026 Healthcare Conference, UBS Global Biopharma Conference, and Jefferies Global Healthcare Conference, all featuring fireside chats. Live webcasts and recordings will be available on the company's investor relations website.
Olema Pharmaceuticals, Inc. (OLMA) Options Chain - Yahoo Finance
This article provides the options chain data for Olema Pharmaceuticals, Inc. (OLMA) as reported on Yahoo Finance. It details various call and put options with an expiration date of January 15, 2027, including strike prices, last trade dates, last prices, and implied volatility. The current stock price of OLMA is noted as $7.07, reflecting real-time NasdaqGS data.
Olema Pharmaceuticals, Inc. (OLMA) Seasonal returns chart
This article provides a seasonal returns chart for Olema Pharmaceuticals, Inc. (OLMA), displaying the average monthly price return between 2020 and 2026. As of October 30, the stock was priced at $7.00.
Olema Pharmaceuticals, Inc. (OLMA) Seasonal Returns Chart - Yahoo Finance
This article provides a seasonal returns chart for Olema Pharmaceuticals, Inc. (OLMA), showing the average monthly price return from 2020 to 2026. The stock closed at $7.00 with a 4.50% decrease on October 30, and remained stable after hours. The page also features a snapshot of various market indices and commodities.
Olema Pharmaceuticals, Inc. Estimates – NASDAQ:OLMA
This page provides access to financial actuals and analyst estimates for Olema Pharmaceuticals, Inc. (NASDAQ: OLMA). Users can explore reported financial data across income statements, balance sheets, cash flow statements, and valuation metrics, comparing actual results with average, high, and low estimates. The platform also allows for visualizing financial trends over time for both annual and quarterly data.
Olema Pharmaceuticals (NASDAQ:OLMA) Shares Up 7.4% - What's Next?
Olema Pharmaceuticals (OLMA) shares rose 7.4% during mid-day trading but with significantly lower volume than average. The clinical-stage biotech recently missed quarterly EPS estimates and has a consensus "Moderate Buy" rating from analysts, with an average price target of $40.60, well above its current price. Insider selling and institutional investor activity also saw recent movements in the company's stock.
Form 13D/A Olema Pharmaceuticals For: 16 October By Investing.com
This article announces the filing of Form 13D/A for Olema Pharmaceuticals on October 16. It briefly mentions the company's stock performance, showing a -4.22% change, and was published by Investing.com.
Form 13D/A Olema Pharmaceuticals For: 16 October By Investing.com
This article announces the filing of Form 13D/A for Olema Pharmaceuticals on October 16. It is a brief, news-style update from Investing.com, indicating a regulatory filing related to the company. The content primarily consists of the headline and a single line mentioning the filing.
A 9.99% ownership cap limits warrant exercises at Olema Pharmaceuticals (OLMA).
BVF Partners LP reported an approximate 9.8% beneficial ownership stake in Olema Pharmaceuticals (OLMA), totaling 8,939,731 shares. A significant aspect of this holding includes pre-funded warrants for 6,373,040 shares, but a 9.99% ownership blocker limits the immediate exercise of these warrants to 3,643,838 shares. Additionally, Gorjan Hrustanovic resigned from Olema's Board and committees, though his departure was not due to disagreements with the company's operations.
Form 13D/A Olema Pharmaceuticals For: 16 October By Investing.com
This article announces the filing of Form 13D/A for Olema Pharmaceuticals on October 16. It is a brief, unelaborated news piece from Investing.com, typical of a regulatory filing announcement. The content is primarily a headline repeated with no further details about the filing's substance.
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Stock Has Consensus Price Target of $40.60 According to Brokerages
Olema Pharmaceuticals (NASDAQ:OLMA) has a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $40.60. Despite recent reductions in price targets by several brokerages, most analysts maintain buy or overweight ratings. The company's shares opened at $7.02, near a 12-month low, and it recently reported a quarterly loss exceeding consensus estimates.
Olema Pharmaceuticals, Inc. (OLMA) Stock Price, News, Quote & History
This Yahoo Finance article provides a detailed overview of Olema Pharmaceuticals, Inc. (OLMA), including its current stock price, trading activity, historical performance, and key financial metrics. It highlights the company's focus on therapies for women's cancers, its clinical-stage pipeline with lead product palazestrant, and analyst insights. The report also includes performance comparisons against the S&P 500 and various financial statistics.
Mammo 2026: OncoDaily and Olema Pharmaceuticals Bring Global Breast Cancer Perspectives Together
OncoDaily and Olema Pharmaceuticals are collaborating for Mammo 2026, a virtual global breast cancer congress held on October 8–9, 2026. The event will cover the entire breast cancer continuum, from screening to metastatic disease and global access to care, bringing together international experts. Olema Oncology is sponsoring the event, highlighting its commitment to developing targeted therapies for endocrine-driven cancers.
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Pharmaceuticals, Inc. ("Olema Oncology") announced that it granted stock options to six new employees to purchase an aggregate of 235,950 shares of the Company's common stock. These grants, effective October 1, 2026, were made under the Company's 2022 Inducement Plan as an inducement for employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options vest over four years with an exercise price of $8.27 per share.
Mammo 2026: OncoDaily and Olema Pharmaceuticals Bring Global Breast Cancer Perspectives Together
OncoDaily and Olema Pharmaceuticals are collaborating for Mammo 2026, a virtual global congress on breast cancer care taking place on October 8-9, 2026. Olema Oncology is a Bronze Sponsor, supporting the international scientific program that will cover the full breast cancer continuum, from screening to survivorship. The congress aims to bring together global experts to discuss advances, challenges, and evolving priorities in breast cancer prevention, diagnosis, treatment, and research.
Bank of America Corp DE Makes New Investment in Olema Pharmaceuticals, Inc. $OLMA
Bank of America Corp DE has acquired a new stake of 334,875 shares, valued at approximately $4.19 million, in Olema Pharmaceuticals Inc. during the second quarter of 2026. This investment makes Bank of America Corp DE an owner of 0.38% of Olema Pharmaceuticals, a clinical-stage biopharmaceutical company. Despite a recent quarterly loss of $0.61 per share and a significant drop from its 52-week high, institutional investors collectively own 91.78% of OLMA, and analysts maintain a "Moderate Buy" rating with an average price target of $40.60.
Olema Pharmaceuticals (NASDAQ:OLMA) Shares Down 7.1% - Time to Sell?
Olema Pharmaceuticals (NASDAQ:OLMA) experienced a 7.1% drop in shares, trading at $8.95 with significantly reduced volume. Despite several analyst price target cuts, the stock maintains a "Moderate Buy" consensus with an average target of $40.60. The decline follows the company missing its latest quarterly earnings estimate, reporting a loss of $0.61 per share against an expected $0.55 loss.
H.C. Wainwright Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Maintains Target Price $36
H.C. Wainwright has reaffirmed its Buy rating for Olema Pharmaceuticals (OLMA.US) and maintained its target price at $36. This indicates continued confidence from the analyst firm in the company's prospects.
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives Average Rating of "Moderate Buy" from Analysts
Olema Pharmaceuticals (NASDAQ:OLMA) has received a consensus "Moderate Buy" rating from thirteen analysts, with an average 12-month price target of $40.60. Despite some recent price target adjustments by JPMorgan and Stifel, and a reiterated buy rating from Citigroup, the company reported a quarterly loss of $0.61 per share, missing estimates. Institutional investors hold approximately 91.78% of the shares, while one director recently sold 12,500 shares.
A Quick Look at Today's Ratings for Olema Pharmaceuticals(OLMA.US), With a Forecast Between $16 to $59
This article provides a quick look at analyst ratings for Olema Pharmaceuticals (OLMA.US), presenting a forecast range between $16 and $59. It is based on a document and implies a review of current market sentiment and price targets for the company.
Olema Pharmaceuticals Shares Fall 15.1% Following AstraZeneca SERENA-4 Trial Results
Olema Pharmaceuticals shares dropped 15.1% in pre-market trading after AstraZeneca's Phase 3 SERENA-4 trial for camizestrant failed to meet its primary endpoint in treating ER-positive, HER2-negative advanced breast cancer. Investors are assessing these results for their potential implications on Olema's lead candidate, palazestrant, which has a similar mechanism and is currently in its own Phase 3 trial. Following this news, Stifel reduced Olema's price target, although it maintained a Buy rating, as the market awaits specific clinical data from Olema's OPERA-01 trial.
Citi Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Maintains Target Price $59
Citi has reiterated its Buy rating for Olema Pharmaceuticals (OLMA.US) and maintained its target price at $59. This indicates a continued positive outlook from the firm regarding the company's stock performance.
Olema Pharmaceuticals (NASDAQ:OLMA) Shares Down 4.4% - Here's Why
Olema Pharmaceuticals (OLMA) shares dropped 4.4% in mid-day trading on Friday, with trading volume significantly lower than average. This decline occurred despite analysts maintaining a "Moderate Buy" consensus rating and an average price target of $42.40, though several price targets have been reduced. The company recently missed its quarterly earnings expectations, reporting a wider loss than anticipated.
Olema Pharmaceuticals, Inc. $OLMA Shares Sold by Squarepoint Ops LLC
Squarepoint Ops LLC reduced its stake in Olema Pharmaceuticals (OLMA) by 28.3% in the second quarter, selling 243,082 shares, though institutional investors still hold 91.78% of the company. Olema reported a Q2 loss of $0.61 per share, missing analyst estimates, with a full-year loss of $2.43 per share anticipated. Despite several recent price target reductions, analysts maintain a "Moderate Buy" rating with an average target of $42.40 for the stock, which currently trades at $10.69.
Olema Pharmaceuticals (NASDAQ:OLMA) Shares Up 3.5% - Should You Buy?
Olema Pharmaceuticals (NASDAQ:OLMA) saw its shares rise by 3.5% to about $10.73, despite a significant 92% drop in trading volume compared to its daily average. The clinical-stage cancer-drug developer, currently in Phase 3 trials for its lead candidate OP-1250 for advanced breast cancer, maintains a "Moderate Buy" consensus rating from analysts with an average target price of $42.40, even after recent price target cuts and missing its latest quarterly EPS estimate. Insider selling and institutional investment adjustments were also noted.
Wellington Management Group LLP Cuts Holdings in Olema Pharmaceuticals, Inc. $OLMA
Wellington Management Group LLP reduced its stake in Olema Pharmaceuticals (NASDAQ:OLMA) by 20.8% in the second quarter, selling 138,233 shares and retaining 526,446 shares valued at $6.6 million. Institutional investors collectively own 91.78% of OLMA, and analysts maintain a "Moderate Buy" consensus with an average price target of $42.40, despite several recent target reductions. The company's stock opened at $10.98, significantly below its 52-week high, and it reported a wider-than-expected quarterly loss of $0.61 per share.
Readystate Asset Management LP Makes New Investment in Olema Pharmaceuticals, Inc. $OLMA
Readystate Asset Management LP has acquired a new stake in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA), purchasing 593,829 shares valued at approximately $7.4 million, representing a 0.68% ownership. This move comes as institutional investors collectively hold a significant 91.78% of the company's stock, despite several analysts lowering price targets for the biotech firm, which is currently conducting Phase 3 trials for a breast cancer treatment.
Bank of New York Mellon Corp Invests $2.78 Million in Olema Pharmaceuticals, Inc. $OLMA
Bank of New York Mellon Corp has acquired a new stake of 222,177 shares in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) worth approximately $2.78 million. Other institutional investors have also adjusted their holdings, with institutional ownership now at 91.78%. Despite analysts maintaining a "Moderate Buy" rating with a $42.40 price target, the company recently missed earnings estimates and a director sold shares.
Olema Pharmaceuticals (NASDAQ: OLMA) grants CFO 650K options expiring in 2036
Olema Pharmaceuticals' Chief Financial Officer, Jason O'Byrne, was granted 650,000 stock options on September 1, 2026, with an exercise price of $10.56 per share and an expiration date of August 31, 2036. The options have a vesting schedule where 25% vest on August 11, 2027, and the remainder vest monthly over the subsequent 36 months, contingent on his continued service. This grant was reported in a Form 4 filing, indicating it was an award rather than a purchase and was not tied to a Rule 10b5-1 trading plan.